Supernus director sells 5,369 shares at $50.6100

SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported an open-market sale of 5,369 shares of Common Stock on March 12, 2026.

Accepted by SEC EDGAR 03/16/2026 - 04:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported an open-market sale of 5,369 shares of Common Stock on March 12, 2026. The weighted average sale price was $50.6100 per share, with trades executed between $50.45 and $50.82. Following this transaction, he directly holds 60,413 shares.

Insider Trade Summary

Net Seller: 5,369 shares

Net Sell 1 txn

Insider Hudson Frederick M.

Role Director

Sold 5,369 shs ($272K)

Share of Position Sold 8.2%

Type	Security	Shares	Price	Value
Sale	Common Stock	5,369	$50.61	$272K

Holdings After Transaction: Common Stock — 60,413 shares (Direct)

Holdings Before and After: Common Stock, 65,782 to 60,413 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Frederick M. Hudson report at SUPN?

Frederick M. Hudson, a director of Supernus Pharmaceuticals, reported selling 5,369 shares of Common Stock. The transaction was an open-market sale and left him with 60,413 shares held directly after the trade, according to the Form 4 filing details.

At what price did the SUPN director sell his shares?

The reported weighted average sale price was $50.6100 per share. According to the filing footnote, individual trades occurred at prices ranging from $50.45 to $50.82, reflecting multiple executions that together produced the stated weighted average transaction price.

How many SUPN shares does Frederick M. Hudson hold after this sale?

After completing the reported sale, Frederick M. Hudson directly holds 60,413 shares of Supernus Pharmaceuticals Common Stock. This post-transaction ownership figure is disclosed in the Form 4 and represents his remaining direct equity position following the 5,369-share disposition.

Was the SUPN insider sale executed in multiple trades?

Yes. The filing states that the price reported is a weighted average and that shares were sold in multiple transactions. These individual trades occurred at prices between $50.45 and $50.82, indicating the total 5,369 shares were not sold in a single trade.

Does this Supernus Form 4 show any option exercises or derivative transactions?

No. The reported activity involves only non-derivative Common Stock sales. The derivative transaction summary is empty, indicating no option exercises, conversions, or other derivative-related movements were reported in this specific Form 4 filing for Frederick M. Hudson.

Does the Form 4 mention how pricing details can be obtained for each trade?

Yes. The footnote explains that the director will provide full information about the number of shares sold at each separate price within the $50.45–$50.82 range to Supernus, any security holder, or the SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hudson Frederick M.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S		5,369	D	$50.61(1)	60,413	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.